

RECEIVED  
CENTRAL FAX CENTER

OCT 04 2005

9194199354

IPTL

02:54:18 p.m.

10-04-2005

1 / 14

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re United States Patent Application of:

Applicant: CHANG, Kwen-Jen, et al.

Application No.: 10/749,437

Date Filed: December 31, 2003

Title: CARDIOPROTECTIVE  
DELTA OPIOID RECEPTOR  
AGONISTS AND METHODS  
OF USING SAME

) Docket No.: 4080-130

) Examiner: Unassigned

) Art Unit: 1614

) Conf. No.: 8959

) Customer No.:

**23448**


**FACSIMILE TRANSMISSION CERTIFICATE**

Fax No. (571) 273-8300

I hereby certify that this document is being filed in the United States Patent and Trademark Office, via facsimile transmission to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on October 4, 2005, to United States Patent and Trademark Office facsimile transmission number (571) 273-8300.

14

Number of Pages (including cover)

  
Joanna Joslyn

October 4, 2005

Date

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this

application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. \_\_\_\_\_ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. \_\_\_\_\_ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. \_\_\_\_\_ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



Marianne Fuierer  
Reg. No. 39,983  
Attorney for Applicants

**INTELLECTUAL PROPERTY/  
TECHNOLOGY LAW**  
Telephone: (919) 419-9350  
Fax: (919) 419-9354  
Attorney Ref: 4080-130

RECEIVED  
CENTRAL FAX CENTER

02:55:07 p.m.

10-04-2005

4 / 14

OCT 04 2005

PTO/SB/08A (01-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Sheet 1 of 3	<b>COMPLETE IF KNOWN</b>	
	Application Number	10/749,437
	Filing Date	December 31, 2003
	First Named Inventor	CHANG, Kwen-Jen, et al.
	Art Unit	1614
	Examiner Name	Unassigned
	Attorney Docket Number	4080-130

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	AI	US-6,200,978		03/13/2001	Maw, et al.
	AJ	US-20020052007	05-02-2002		Chang, et al.
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Examiner signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>1</sup> All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. § 1.98(a)(3)(i), according to MPEP 609 III A(3).



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Sheet 3 of 3	<i>COMPLETE IF KNOWN</i>	
	Application Number	10/749,437
	Filing Date	December 31, 2003
	First Named Inventor	CHANG, Kwen-Jen, et al.
	Art Unit	1614
	Examiner Name	Unassigned
	Attorney Docket Number	4080-130

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AL	ITO et al., "U-92032, a T-type Ca <sup>2+</sup> channel blocker and antioxidant, reduces neuronal ischemic injuries", European Journal of Pharmacology, (1994), 257, 203-325.	

Examiner signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

<sup>2</sup> Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).